Leukemia Research
Volume 26, Issue 11 , Pages 1011-1016 , November 2002

The kinase inhibitor STI571 reverses the Bcr–Abl induced point mutation frequencies observed in pre-leukemic P190Bcr–Abl transgenic mice

Received 22 May 2001 ,Accepted 22 October 2001.

References 

  1. Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290–293
  2. Voncken JW, van Schaick H, Kaartinen V, et al.  Increased neutrophil respiratory burst in Bcr-null mutants. Cell. 1995;80:719–728
  3. Welch PJ, Wang JY. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle. Cell. 1993;75:779–790
  4. Wen ST, Jackson PK, Van Etten RA. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products. EMBO J. 1996;15:1583–1595
  5. Sawyers CL. The Bcr–Abl gene in chronic myelogenous leukaemia. Cancer Surv. 1992;15:37–51
  6. Bernstein R. Cytogenetics of chronic myelogenous leukemia. Semin. Hematol. 1988;25:20–34
  7. Laneuville P, Timm M, Hudson AT. Bcr–Abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. Cancer Res. 1994;54:1360–1366
  8. Salloukh HF, Laneuville P. Increase in mutant frequencies in mice expressing the Bcr–Abl activated tyrosine kinase. Leukemia. 2000;14:1401–1404
  9. Dycaico MJ, Stuart GR, Tobal GM, de Boer JG, Glickman BW, Provost GS. Species-specific differences in hepatic mutant frequency and mutational spectrum among lambda/LacI transgenic rats and mice following exposure to aflatoxin B1. Carcinogenesis. 1996;17:2347–2356
  10. Skopek TR, Kort KL, Marino DR, et al.  Mutagenic response of the endogenous hprt gene and LacI transgene in benzo[a]pyrene-treated Big Blue B6C3F1 mice. Environ. Mol. Mutagen. 1996;28:376–384
  11. Druker BJ, Tamura S, Buchdunger E, et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells. Natl. Med. 1996;2:561–566
  12. Voncken JW, Morris C, Pattengale P, et al.  Clonal development and karyotype evolution during leukemogenesis of Bcr–Abl transgenic mice. Blood. 1992;79:1029–1036
  13. Melo JV. The diversity of Bcr–Abl fusion proteins and their relationship to leukemia phenotype. Blood. 1996;88:2375–2384
  14. Tsurimoto T, Stillman B. Purification of a cellular replication factor, RF-C, that is required for coordinated synthesis of leading and lagging strands during simian virus 40 DNA replication in vitro. Mol. Cell Biol. 1989;9:609–619
  15. Shiomi Y, Usukura J, Masamura Y, et al.  ATP-dependent structural change of the eukaryotic clamp-loader protein, replication factor C. Proc. Natl. Acad. Sci. U.S.A. 2000;97:14127–14132
  16. Tsurimoto T, Stillman B. Functions of replication factor C and proliferating-cell nuclear antigen: functional similarity of DNA polymerase accessory proteins from human cells and bacteriophage T4. Proc. Natl. Acad. Sci. U.S.A. 1990;87:1023–1027
  17. Zhang G, Gibbs E, Kelman Z, O’Donnell M, Hurwitz J. Studies on the interactions between human replication factor C and human proliferating cell nuclear antigen. Proc. Natl. Acad. Sci. U.S.A. 1999;96:1869–1874
  18. Banin S, Moyal L, Shieh S, et al.  Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 1998;281:1674–1677
  19. Baskaran R, Wood LD, Whitaker LL, et al.  Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation. Nature. 1997;387:516–519
  20. Shafman T, Khanna KK, Kedar P, et al.  Interaction between ATM protein and c-Abl in response to DNA damage. Nature. 1997;387:520–523
  21. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature. 1999;399:809–813
  22. Chen G, Yuan SS, Liu W, et al.  Radiation-induced assembly of Rad51 and Rad52 recombination complex requires ATM and c-Abl. J. Biol. Chem. 1999;274:12748–12752
  23. Gong JG, Costanzo A, Yang HQ, et al.  The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399:806–809
  24. White E, Prives C. DNA damage enables p73. Nature 1999;399:734–5, 737.
  25. Yuan ZM, Huang Y, Ishiko T, et al.  Regulation of Rad51 function by c-Abl in response to DNA damage. J. Biol. Chem. 1998;273:3799–3802
  26. Yuan ZM, Shioya H, Ishiko T, et al.  p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 1999;399:814–817
  27. le Coutre P, Mologni L, Cleris L, et al.  In vivo eradication of human Bcr–Abl-positive leukemia cells with an ABL kinase inhibitor. J. Natl. Cancer. Inst. 1999;91:163–168

PII: S0145-2126(01)00181-3

Leukemia Research
Volume 26, Issue 11 , Pages 1011-1016 , November 2002

Article Tools

* Image Usage & Resolution